Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohnʼs Disease

R. Rosh, Joel; Lerer, Trudy; Markowitz, James; R. Goli, Sri; Mamula, Petar; D. Noe, Joshua; D. Pfefferkorn, Marian; T. Kelleher, Kathleen; M. Griffiths, Anne; Kugathasan, Subra; J. Keljo, David; Oliva‐Hemker, Maria; Crandall, Wallace; Carvalho, Ryan; Mack, David; S. Hyams, Jeffrey

doi:10.1038/ajg.2009.493

Public

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohnʼs Disease

Published in The American Journal of Gastroenterology • Sep 1, 2009

Authors:

Joel R. Rosh

Trudy Lerer

James Markowitz

Abstract

OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is increasingly being reported as a potential treatment option for children with moderate-to-severe Crohn's disease (CD). The aim of this study was to characterize common indications, safety, tolerability, and clinical ...

Subject

Adalimumab

Medicine

Infliximab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!